Ann R. Thomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ann R. Thomas has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Nancy M. Bennett
University of Rochester School of Medicine and Dentistry
2 shared publications Paul R. Cieslak
2 shared publications- Ruth Lynfield
Minnesota Department of Health
2 shared publications - Shikha Garg
National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia
2 shared publications - William Schaffner
Vanderbilt University School of Medicine, Nashville, TN, USA
2 shared publications - Alejandro Pérez
Epidemiology and Prevention Branch, Influenza Division, CDC, 1600 Clifton Road, Atlanta, GA, USA.
1 shared publication
Latest Publications
- Open Access
- 26 August 2015
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 15 (1) , 1-9
Pneumonia among adults hospitalized with laboratory-confirmed seasonal influenza virus infection—United States, 2005–2008
Influenza and pneumonia combined are the leading causes of death due to infectious diseases in the United States. We describe factors associated with pneumonia among adults hospitalized with influenza. Through the Emerging Infections Program, we identified adults ≥ 18 years, who were hospitalized with laboratory-confirmed influenza during October 2005 through April 2008, and had a chest radiograph (CXR) performed. Pneumonia was defined as the presence of a CXR infiltrate and either an ICD-9-CM code or discharge summary diagnosis of pneumonia. Among 4,765 adults hospitalized with influenza, 1392 (29 %) had pneumonia. In multivariable analysis, factors associated with pneumonia included: age ≥ 75 years, adjusted odds ratio (AOR) 1.27 (95 % confidence interval 1.10–1.46), white race AOR 1.24 (1.03–1.49), nursing home residence AOR 1.37 (1.14–1.66), chronic lung disease AOR 1.37 (1.18–1.59), immunosuppression AOR 1.45 (1.19–1.78), and asthma AOR 0.76 (0.62–0.92). Patients with pneumonia were significantly more likely to require intensive care unit (ICU) admission (27 % vs. 10 %), mechanical ventilation (18 % vs. 5 %), and to die (9 % vs. 2 %). Pneumonia was present in nearly one-third of adults hospitalized with influenza and was associated with ICU admission and death. Among patients hospitalized with influenza, older patients and those with certain underlying conditions are more likely to have pneumonia. Pneumonia is common among adults hospitalized with influenza and should be evaluated and treated promptly.
- 26 August 2015
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 15 (1) , 1-9
Open AccessPneumonia among adults hospitalized with laboratory-confirmed seasonal influenza virus infection—United States, 2005–2008
Influenza and pneumonia combined are the leading causes of death due to infectious diseases in the United States. We describe factors associated with pneumonia among adults hospitalized with influenza. Through the Emerging Infections Program, we identified adults ≥ 18 years, who were hospitalized with laboratory-confirmed influenza during October 2005 through April 2008, and had a chest radiograph (CXR) performed. Pneumonia was defined as the presence of a CXR infiltrate and either an ICD-9-CM code or discharge summary diagnosis of pneumonia. Among 4,765 adults hospitalized with influenza, 1392 (29 %) had pneumonia. In multivariable analysis, factors associated with pneumonia included: age ≥ 75 years, adjusted odds ratio (AOR) 1.27 (95 % confidence interval 1.10–1.46), white race AOR 1.24 (1.03–1.49), nursing home residence AOR 1.37 (1.14–1.66), chronic lung disease AOR 1.37 (1.18–1.59), immunosuppression AOR 1.45 (1.19–1.78), and asthma AOR 0.76 (0.62–0.92). Patients with pneumonia were significantly more likely to require intensive care unit (ICU) admission (27 % vs. 10 %), mechanical ventilation (18 % vs. 5 %), and to die (9 % vs. 2 %). Pneumonia was present in nearly one-third of adults hospitalized with influenza and was associated with ICU admission and death. Among patients hospitalized with influenza, older patients and those with certain underlying conditions are more likely to have pneumonia. Pneumonia is common among adults hospitalized with influenza and should be evaluated and treated promptly.
- Open Access
- 13 December 2011
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 205 (1) , 13-19
Association Between Use of Statins and Mortality Among Patients Hospitalized With Laboratory-Confirmed Influenza Virus Infections: A Multistate Study
(See the editorial commentary by Walsh, on pages 1–3 .) Background. Statins may have anti-inflammatory and immunomodulatory effects that could reduce the risk of mortality from influenza virus infections. Methods. The Centers for Disease Control and Prevention’s Emerging Infections Program conducts active surveillance for persons hospitalized with laboratory-confirmed influenza in 59 counties in 10 states. We analyzed data for hospitalized adults during the 2007–2008 influenza season to evaluate the association between receiving statins and influenza-related death. Results. We identified 3043 patients hospitalized with laboratory-confirmed influenza, of whom 1013 (33.3%) received statins and 151 (5.0%) died within 30 days of their influenza test. Patients who received statins were more likely to be older, male, and white; to suffer from cardiovascular, metabolic, renal, and chronic lung disease; and to have been vaccinated against influenza that season. In a multivariable logistic regression model, administration of statins prior to or during hospitalization was associated with a protective odds of death (adjusted odds ratio, 0.59 [95% confidence interval, .38–.92]) when adjusting for age; race; cardiovascular, lung, and renal disease; influenza vaccination; and antiviral administration. Conclusions. Statin use may be associated with reduced mortality in patients hospitalized with influenza.
- 13 December 2011
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 205 (1) , 13-19
Open AccessAssociation Between Use of Statins and Mortality Among Patients Hospitalized With Laboratory-Confirmed Influenza Virus Infections: A Multistate Study
(See the editorial commentary by Walsh, on pages 1–3 .) Background. Statins may have anti-inflammatory and immunomodulatory effects that could reduce the risk of mortality from influenza virus infections. Methods. The Centers for Disease Control and Prevention’s Emerging Infections Program conducts active surveillance for persons hospitalized with laboratory-confirmed influenza in 59 counties in 10 states. We analyzed data for hospitalized adults during the 2007–2008 influenza season to evaluate the association between receiving statins and influenza-related death. Results. We identified 3043 patients hospitalized with laboratory-confirmed influenza, of whom 1013 (33.3%) received statins and 151 (5.0%) died within 30 days of their influenza test. Patients who received statins were more likely to be older, male, and white; to suffer from cardiovascular, metabolic, renal, and chronic lung disease; and to have been vaccinated against influenza that season. In a multivariable logistic regression model, administration of statins prior to or during hospitalization was associated with a protective odds of death (adjusted odds ratio, 0.59 [95% confidence interval, .38–.92]) when adjusting for age; race; cardiovascular, lung, and renal disease; influenza vaccination; and antiviral administration. Conclusions. Statin use may be associated with reduced mortality in patients hospitalized with influenza.
- 1 October 2007
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 41 (9) , 859-862
Deaths From Chronic Liver Disease and Viral Hepatitis, Multnomah County, Oregon, 2000
Goals Identify deaths related to chronic liver disease (CLD) in 2000 among Multnomah County, Oregon residents and estimate the proportion of these deaths attributable to hepatitis B or hepatitis C. Background Although CLD is among the most common causes of mortality in the United States, little information is available regarding the proportion of CLD mortality attributable to viral hepatitis. Study We developed a comprehensive list of 117 International Classification of Disease-10 codes potentially related to CLD. We identified deaths among residents of Multnomah County, Oregon whose death certificates included any one of these 117 codes. We verified the history of CLD and viral hepatitis using a combination of hospital charts, medical examiner reports, and a clinical questionnaire mailed to the certifying physician. Results We verified that 118 patients had died of CLD in Multnomah County, Oregon in 2000; 38 (32%) of the death certificates listed hepatitis B or hepatitis C as the underlying or a contributing cause of death. By medical record review, an additional 16 patients were found to have hepatitis B or hepatitis C not indicated on the death certificate [total 54 (46%) patients with viral hepatitis]. The majority of the 38 patients with viral hepatitis listed on the death certificate had an International Classification of Disease-10 code indicating acute infection with hepatitis B or hepatitis C. Conclusions Chronic viral hepatitis is often unreported on death certificates of patients with CLD and, when reported, may be incorrectly coded as acute instead of chronic infection.
- 1 October 2007
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 41 (9) , 859-862
Deaths From Chronic Liver Disease and Viral Hepatitis, Multnomah County, Oregon, 2000
Goals Identify deaths related to chronic liver disease (CLD) in 2000 among Multnomah County, Oregon residents and estimate the proportion of these deaths attributable to hepatitis B or hepatitis C. Background Although CLD is among the most common causes of mortality in the United States, little information is available regarding the proportion of CLD mortality attributable to viral hepatitis. Study We developed a comprehensive list of 117 International Classification of Disease-10 codes potentially related to CLD. We identified deaths among residents of Multnomah County, Oregon whose death certificates included any one of these 117 codes. We verified the history of CLD and viral hepatitis using a combination of hospital charts, medical examiner reports, and a clinical questionnaire mailed to the certifying physician. Results We verified that 118 patients had died of CLD in Multnomah County, Oregon in 2000; 38 (32%) of the death certificates listed hepatitis B or hepatitis C as the underlying or a contributing cause of death. By medical record review, an additional 16 patients were found to have hepatitis B or hepatitis C not indicated on the death certificate [total 54 (46%) patients with viral hepatitis]. The majority of the 38 patients with viral hepatitis listed on the death certificate had an International Classification of Disease-10 code indicating acute infection with hepatitis B or hepatitis C. Conclusions Chronic viral hepatitis is often unreported on death certificates of patients with CLD and, when reported, may be incorrectly coded as acute instead of chronic infection.
- 30 November 2005
- Published by Elsevier in Journal of Adolescent Health
- Vol. 37 (5) , 410-413
Seroprevalence of hepatitis B and C in juvenile detention entrants, Oregon, 1994–1996
- 30 November 2005
- Published by Elsevier in Journal of Adolescent Health
- Vol. 37 (5) , 410-413
Seroprevalence of hepatitis B and C in juvenile detention entrants, Oregon, 1994–1996
- 1 April 2004
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 23 (4) , 313-318
Hepatitis B vaccine coverage among infants born to women without prenatal screening for hepatitis B virus infection: effects of the Joint Statement on Thimerosal in Vaccines
As a result of controversy about mercury exposures from vaccines containing thimerosal, the American Academy of Pediatrics and the US Public Health Service recommended in July 1999 that the first dose of hepatitis B vaccine be deferred until 2 to 6 months of age, but only for infants born to hepatitis B surface antigen (HBsAg)-negative women. We investigated the effect of these recommendation changes on the management of Oregon infants born to women whose HBsAg status was “unknown.” Infants were identified by reviewing electronic birth certificate data from 34 Oregon hospitals during (1)April through June 1999 [before recommendation changes (T1)], (2) August through October 1999 [after recommendations changes (T2)] and (3) April through June 2000 [when resumption of pre-1999 practices were recommended (T3)]. We verified maternal HBsAg screening and newborn hepatitis B vaccination by chart review. We identified 147 infants born to women who were not screened for HBsAg. During T1, 27% of infants born to mothers of unknown HBsAg status were vaccinated within 12 h of birth, and 80% were vaccinated before hospital discharge. This decreased to 2 and 4%, respectively, during T2 and continued to remain lower during T3. Hepatitis B vaccine coverage for infants born to unscreened women declined significantly after the July 1999 announcement and remained significantly lower 10 to 12 months later. When changes are made in established vaccination practices, policy makers should ensure that such changes are not misinterpreted, resulting in failure to immunize appropriate groups.
- 1 April 2004
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 23 (4) , 313-318
Hepatitis B vaccine coverage among infants born to women without prenatal screening for hepatitis B virus infection: effects of the Joint Statement on Thimerosal in Vaccines
As a result of controversy about mercury exposures from vaccines containing thimerosal, the American Academy of Pediatrics and the US Public Health Service recommended in July 1999 that the first dose of hepatitis B vaccine be deferred until 2 to 6 months of age, but only for infants born to hepatitis B surface antigen (HBsAg)-negative women. We investigated the effect of these recommendation changes on the management of Oregon infants born to women whose HBsAg status was “unknown.” Infants were identified by reviewing electronic birth certificate data from 34 Oregon hospitals during (1)April through June 1999 [before recommendation changes (T1)], (2) August through October 1999 [after recommendations changes (T2)] and (3) April through June 2000 [when resumption of pre-1999 practices were recommended (T3)]. We verified maternal HBsAg screening and newborn hepatitis B vaccination by chart review. We identified 147 infants born to women who were not screened for HBsAg. During T1, 27% of infants born to mothers of unknown HBsAg status were vaccinated within 12 h of birth, and 80% were vaccinated before hospital discharge. This decreased to 2 and 4%, respectively, during T2 and continued to remain lower during T3. Hepatitis B vaccine coverage for infants born to unscreened women declined significantly after the July 1999 announcement and remained significantly lower 10 to 12 months later. When changes are made in established vaccination practices, policy makers should ensure that such changes are not misinterpreted, resulting in failure to immunize appropriate groups.
- Open Access
- 1 June 2001
- Published by BMJ in Tobacco Control
- Vol. 10 (2) , 161-164
Comparison of physician based reporting of tobacco attributable deaths and computer derived estimates of smoking attributable deaths, Oregon, 1989 to 1996
BACKGROUND Tobacco use prevention programmes need accurate information about smoking related mortality. Beginning in 1989, Oregon began asking physicians to report on death certificates whether tobacco use contributed to the death. OBJECTIVE To determine the long term comparability of this method of estimating tobacco attributable mortality to estimates of smoking attributable mortality derived from a computer model. DESIGN For the period 1989 to 1996, we compared mortality resulting from tobacco use reported by Oregon physicians to estimates of smoking attributable deaths (SADs) derived by “Smoking attributable mortality, morbidity and economic costs” software version 3.0 (SAMMEC 3.0), a widely used software program that estimates SADs on the basis of smoking prevalence and relative risks of specific diseases among current and former smokers. MAIN OUTCOME MEASURES Numbers of deaths, age, sex, and category of disease. RESULTS Of 212 448 Oregon deaths during 1989–1996, SAMMEC 3.0 estimated that 42 778 (20.1%) were attributable to cigarette smoking. For the same 27 diagnoses, physicians reported that tobacco contributed to 42 839 (20.2%) deaths—a cumulative difference of only 61 deaths over the eight year period. The age and sex distributions of tobacco and smoking attributable deaths reported by the two systems were also similar. By category of disease, the ratio of SAMMEC 3.0 estimates to physician reported deaths was 1.11 for neoplasms, 0.88 for heart disease, and 1.04 for respiratory disease. CONCLUSIONS Physician reporting provides comparable estimates of smoking attributable mortality and can be a valuable source of data for communicating the risks of tobacco use to the public.
- 1 June 2001
- Published by BMJ in Tobacco Control
- Vol. 10 (2) , 161-164
Open AccessComparison of physician based reporting of tobacco attributable deaths and computer derived estimates of smoking attributable deaths, Oregon, 1989 to 1996
BACKGROUND Tobacco use prevention programmes need accurate information about smoking related mortality. Beginning in 1989, Oregon began asking physicians to report on death certificates whether tobacco use contributed to the death. OBJECTIVE To determine the long term comparability of this method of estimating tobacco attributable mortality to estimates of smoking attributable mortality derived from a computer model. DESIGN For the period 1989 to 1996, we compared mortality resulting from tobacco use reported by Oregon physicians to estimates of smoking attributable deaths (SADs) derived by “Smoking attributable mortality, morbidity and economic costs” software version 3.0 (SAMMEC 3.0), a widely used software program that estimates SADs on the basis of smoking prevalence and relative risks of specific diseases among current and former smokers. MAIN OUTCOME MEASURES Numbers of deaths, age, sex, and category of disease. RESULTS Of 212 448 Oregon deaths during 1989–1996, SAMMEC 3.0 estimated that 42 778 (20.1%) were attributable to cigarette smoking. For the same 27 diagnoses, physicians reported that tobacco contributed to 42 839 (20.2%) deaths—a cumulative difference of only 61 deaths over the eight year period. The age and sex distributions of tobacco and smoking attributable deaths reported by the two systems were also similar. By category of disease, the ratio of SAMMEC 3.0 estimates to physician reported deaths was 1.11 for neoplasms, 0.88 for heart disease, and 1.04 for respiratory disease. CONCLUSIONS Physician reporting provides comparable estimates of smoking attributable mortality and can be a valuable source of data for communicating the risks of tobacco use to the public.